User profiles for Ahmad Masri
Ahmad MasriOregon Health and Science University Verified email at ohsu.edu Cited by 3467 |
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
…, A Oreziak, R Barriales-Villa, TP Abraham, A Masri… - The Lancet, 2020 - thelancet.com
Background Cardiac muscle hypercontractility is a key pathophysiological abnormality in
hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (…
hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (…
Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy
MS Maron, A Masri, L Choudhury, I Olivotto… - Journal of the American …, 2023 - jacc.org
Background Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart
failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in-…
failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in-…
Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis
…, AJ Sehnert, RY Kwong, M Jerosch-Herold, A Masri… - Circulation, 2021 - Am Heart Assoc
CORRESPONDENCE index ([(1− global extracellular volume fraction)× LV mass]/body
surface index) decreased with mavacamten (− 14.1 [9.5] g/m2) versus no change in placebo (− …
surface index) decreased with mavacamten (− 14.1 [9.5] g/m2) versus no change in placebo (− …
Contemporary natural history of bicuspid aortic valve disease: a systematic review
We performed a systematic review of the current state of the literature regarding the natural
history and outcomes of bicuspid aortic valve (BAV). PubMed and the reference lists of the …
history and outcomes of bicuspid aortic valve (BAV). PubMed and the reference lists of the …
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
…, M Grogan, M Hanna, J Hoffman, A Masri… - … England Journal of …, 2024 - Mass Medical Soc
Background Transthyretin amyloid cardiomyopathy is characterized by the deposition of
misfolded monomeric transthyretin (TTR) in the heart. Acoramidis is a high-affinity TTR stabilizer …
misfolded monomeric transthyretin (TTR) in the heart. Acoramidis is a high-affinity TTR stabilizer …
Vigorous exercise in patients with hypertrophic cardiomyopathy
Importance Whether vigorous intensity exercise is associated with an increase in risk of
ventricular arrhythmias in individuals with hypertrophic cardiomyopathy (HCM) is unknown. …
ventricular arrhythmias in individuals with hypertrophic cardiomyopathy (HCM) is unknown. …
Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study
W Wu, A Masri, ZB Popovic, NG Smedira, BW Lytle… - Circulation, 2013 - Am Heart Assoc
Background— Thoracic radiation results in radiation-associated heart disease (RAHD), often
requiring cardiothoracic surgery (CTS). We sought to measure long-term survival in RAHD …
requiring cardiothoracic surgery (CTS). We sought to measure long-term survival in RAHD …
Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis
H Rosenblum, A Masri, DL Narotsky… - European Journal of …, 2021 - Wiley Online Library
Aims Advances in diagnostic imaging have increased the recognition of coexisting
transthyretin cardiac amyloidosis (ATTR‐CA) and severe aortic stenosis (AS), with a reported …
transthyretin cardiac amyloidosis (ATTR‐CA) and severe aortic stenosis (AS), with a reported …
[HTML][HTML] Global incidence of sports-related sudden cardiac death
Sports-related sudden cardiac death (SrSCD) is a catastrophic event and a leading medical
cause of death in athletes (1). The incidence of SrSCD is debated with estimates ranging …
cause of death in athletes (1). The incidence of SrSCD is debated with estimates ranging …
[HTML][HTML] Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review
…, A van Doornewaard, N Dasgupta, A Masri… - Cardiology and …, 2021 - Springer
Introduction Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, fatal and
under-recognized disease. This targeted literature review assessed the extent and …
under-recognized disease. This targeted literature review assessed the extent and …